ADVIL LIQUI-GELS (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1995.
Drug data last refreshed 8h ago · AI intelligence enriched 5d ago
ADVIL LIQUI-GELS is an oral ibuprofen capsule formulated for rapid absorption and pain relief. It works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain across multiple indications. The product is a nonsteroidal anti-inflammatory drug (NSAID) designed for over-the-counter consumer use.
As a mature OTC product with LOE approaching, teams are rightsizing and shifting focus to adjacent opportunities and generic transition management.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on ADVIL LIQUI-GELS at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ADVIL LIQUI-GELS offers stable, operationally-focused experience in a mature OTC franchise under LOE transition. Career growth is limited to optimization and cost management; advancement requires moving to growth-stage or pipeline assets within GSK's portfolio.